Holen Sie sich die Stockscreener-App
1.88
5.53%
-0.11
Vorhandelsmarkt:
1.84
-0.04
-2.13%
Schlusskurs vom Vortag:
$1.99
Offen:
$1.92
24-Stunden-Volumen:
96,028
Relative Volume:
0.01
Marktkapitalisierung:
$8.53M
Einnahmen:
$6.16M
Nettoeinkommen (Verlust:
$-14.91M
KGV:
-0.1762
EPS:
-10.6693
Netto-Cashflow:
$-9.39M
1W Leistung:
-7.39%
1M Leistung:
-35.84%
6M Leistung:
+2.17%
1J Leistung:
-69.52%
1-Tages-Spanne:
$1.88
$1.99
1-Wochen-Bereich:
$1.86
$2.1797
52-Wochen-Spanne:
$0.693
$15.00
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Firmenname
Bioaffinity Technologies Inc
Sektor
Branche
Telefon
210-698-5334
Adresse
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
1.88 | 9.02M | 6.16M | -14.91M | -9.39M | -10.67 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Bioaffinity Technologies Inc Aktie (BIAF) Neueste Nachrichten
bioAffinity Technologies Inc (BIAF) Stock Price, Quote, News & History - Benzinga
bioAffinity Technologies, Inc.Warrant (NQ: BIAFW - FinancialContent
bioAffinity (BIAF) registers 497,483 resale shares, includes 365,603 warrants - Stock Titan
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung - Yahoo Finance
[EFFECT] bioAffinity Technologies, Inc. SEC Filing - Stock Titan
bioAffinity reports 300% jump in lung test sales in April - Investing.com UK
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Ye - PharmiWeb.com
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 - 01net
bioAffinity Technologies Reports Record 300% Growth in CyPath® Lung Diagnostic Test Sales in April 2026 - Minichart
bioAffinity CyPath Lung Test Sales Surge Sharply - TipRanks
TradingKey - TradingKey
bioAffinity reports 300% jump in lung test sales in April By Investing.com - Investing.com Australia
bioAffinity Reports Record Monthly CyPath Lung Unit Sales, April Up Nearly 300% - TradingView
Record CyPath Lung growth at bioAffinity (NASDAQ: BIAF) with April unit sales up nearly 300% - Stock Titan
bioAffinity Technologies, Inc. 2026 Q1 10-Q Filing: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
bioAffinity Technologies reports net loss of USD 3.6M in Q1 2026 - Medical Buyer
bioAffinity Technologies, Inc. 1Q 2026: Revenue $1.35M, EPS $(0.81) — 10-Q Summary - TradingView
BioAffinity Technologies : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Number of shareholders of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
Q1 2026 loss deepens at bioAffinity Technologies (NASDAQ: BIAF) - Stock Titan
bioAffinity Technologies Releases Q1 2026 Financial Results - AlphaStreet
BIAF | bioAffinity Technologies, Inc. Common Insider Trading - Quiver Quantitative
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung - BioSpace
Bioaffinity Technologies IncQ1 2026 net loss $3.6 million or $0.81 per share - marketscreener.com
BioAffinity Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CyPath Lung growth stands out in bioAffinity (NASDAQ: BIAF) Q1 2026 results - Stock Titan
Press Release: BioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath(R) Lung - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
bioAffinity Shareholders Approve Equity Plan and Capital Measures - TipRanks
Investors in bioAffinity (NASDAQ: BIAF) register 497,483 shares for resale - Stock Titan
8-K: Current report - Moomoo
bioAffinity Technologies (BIAF) wins approval for major equity plan, offerings and reverse split - Stock Titan
BioAffinity stock surges 113.8% in 3 months: What's driving the rally? - MSN
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment - BioSpace
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss - MSN
BIAF stock gains as CyPath sales surge 146% in Q1 - MSN
FinancialContentbioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment - FinancialContent
bioAffinity Technologies prices $4.8 million public offering; shares down over 30% - MSN
bioAffinity Technologies Working With U.S. Army on CyPath Lung Study - Medical Product Outsourcing
Finanzdaten der Bioaffinity Technologies Inc-Aktie (BIAF)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):